TRANSLATIONAL MEDICINE ACADEMY

HIGH SCIENCE HDL FORUM

THE ROLE OF HDL MODIFYING THERAPY FOR THE PREVENTION OF CARDIOVASCULAR DISEASE

Expert Panel Advisory Board

November 11-13, 2015 – Hilton, **ORLANDO**

The Translational Medicine Academy (TMA) is an international academic foundation with focused activities in mission critical areas of high public health importance having significant professional and patient therapeutic and educational gaps

Why a High Science HDL Forum?
The science of dyslipidemia and preventive cardiology is rapidly advancing. While most of the available educational activities are concerned with lowering LDL cholesterol, there is a strong need to bring healthcare providers up-to-date on HDL related knowledge and therapeutics. The emergence of transformative concepts in HDL biology presents challenges for the research and clinician scientist concerning the relevance of certain studies to human atherosclerotic cardiovascular disease. This High Science HDL Forum by TMA is an expert faculty panel forum to discuss these issues with a particular focus on the genetics of HDL therapies.

The objectives of the Forum are
- Discuss current advances in HDL science, including limitations of HDL as a biomarker, HDL dysfunction, and genetic associations of HDL lipoproteins with atherosclerotic cardiovascular disease.
- Review clinical trial data in HDL genetics and therapeutic targets, such as CETP inhibitors.
- Apply pharmacogenomics as a strategy for targeting HDL therapeutics, as well as their potential role in the treatment framework.
- Identify knowledge gaps in our understanding HDL as a therapeutic target.

Leading international Key Opinion Leaders in HDL will deliver the most advanced knowledge on these topics.

PROGRAMME

Wednesday Nov. 11th

BUFFET

1 p.m. - 1.30 p.m.
Welcome speech - objectives & agenda from the Co-Chair
Robert S. Rosenson & H. Bryan Brewer

1.30 p.m. - 2.00 p.m.
Advances in HDL Science *Robert S. Rosenson*
- Impact of HDL summits
- Limitations of HDL cholesterol as a basis as a biomarker of HDL function and HDL dysfunction

2.00 p.m. - 2.30 p.m.
Experimental models: Causal pathways between HDL pathways and atherosclerosis *Kerry Ann Rye*

2.30 p.m. - 3.00 p.m. DISCUSSION

3.00 p.m. - 3.30 p.m.
Control of HDL subclasses *Frank Sacks*

3.30 p.m. - 4.00 p.m. COFFEE BREAK

4.00 p.m. - 4.30 p.m.
HDL proteomics and atherosclerotic cardiovascular disease
Jay Heinecke

4.30 p.m. - 5.00 p.m.
HDL lipidomics and atherosclerotic cardiovascular disease
John Chapman

5.00 p.m. - 6.30 p.m.
DISCUSSION & POST MEETING REPORT PREPARATION

7.00 p.m. DINNER

Thursday Nov. 12th

8.00 a.m. - 8.30 a.m.
Monogenic disorders of HDL and associations with atherosclerotic cardiovascular disease *H. Bryan Brewer*

8.30 a.m. - 9.00 a.m.
CETP: monogenic disorders *Philip Barter*

9.00 a.m. - 9.30 a.m. DISCUSSION

9.30 a.m. - 10.00 a.m.
Genetic associations between lipids/lipoproteins and atherosclerotic cardiovascular disease: HDL *Robert Hegele*

10.00 a.m. - 10.30 a.m.
Genetic associations between lipids/lipoproteins and atherosclerotic cardiovascular disease: Triglyceride rich Lipoproteins *Daniel Gaudet*

10.30 a.m. - 11.00 a.m
Systems Biology in the evaluation of genetically determined risk *Johan Bjorkegren*

11.00 p.m. - 12.00 p.m. DISCUSSION

01:00 p.m. - 01.30 p.m. LUNCH

01.30 p.m. - 02.00 p.m.
CETP: experimental models and clinical trials *Philip Barter*

02.00 p.m. - 02.30 p.m.
Phospholipid Transfer Protein: genetics, experimental models *Daniel Seung Kim*

02.30 p.m. - 03.00 p.m. DISCUSSION

03.00 p.m. - 03.30 p.m.
Pharmacogenomics as a strategy for targeting HDL therapies *Jean-Claude Tardif*

03.30 p.m. - 04.00 p.m.
Criteria for establishing a viable therapeutic HDL target *H. Bryan Brewer*

04.00 p.m. - 05.30 p.m.
DISCUSSION & POST MEETING REPORT PREPARATION

05.30 p.m. - 07.00 p.m.
Video preparation

07.00 p.m. DINNER

Friday Nov. 13th

9.00 a.m
Video implementation

FACULTY

Robert S. Rosenson
MD - Icahn School of Medicine at Mount Sinai - New York, NY (co-chair)

H. Bryan Brewer, Jr.
MD - MedStar Research Institute - Washington, DC (co-chair)

Philip Barter
MD - University of New South Wales – Australia

Johan Bjorkegren
Mount Sinai Icahn School of Medicine - New York NY

John Chapman
PhD- National Institutes for Health and Medical Research - Pitie-Salpetriere University Hospital - Paris, France

Daniel Gaudet
MD, PhD - Dept of medicine, Université de Montreal and Genome Quebec Biobank - Canada

Robert Hegele
MD, Western University - London ON Canada

Jay Heinecke
MD - University of Washington, Seattle - Seattle, WA

Daniel Seung Kim
PhD - University of Washington - Seattle, WA

Kerry Ann Rye
Ph.D - University of New South Wales - Australia

Frank Sacks
MD - School of Public Health - Harvard University - Boston, MA

Jean-Claude Tardif
MD - Montreal Heart Institute - Montreal, Canada

HOW TO JOIN THE FORUM

Where?

HILTON ORLANDO
6001 Destination Parkway
Orlando FL 32819
Tel. +1-407-313-4300

Location:

11 miles from Orlando International Airport
10 miles from Florida Turnpike
3,5 miles from I-4 East

Need more information?
TMA Foundation
Email: info@translationalmedicineacademy.org

REGISTRATION

Registration on TMA website: www.translationalmedicineacademy.org

TMA TRANSLATIONAL MEDICINE ACADEMY